News Release

Third dose of Pfizer-BioNTech vaccine, incidence of SARS-CoV-2 infection, hospitalization, death

JAMA Network Open

Peer-Reviewed Publication

JAMA Network

About The Study: This study of 18,000 residents of long-term care facilities in Israel found that those who had received a third dose (first booster dose) of the Pfizer-BioNTech vaccine had a significantly lower risk for overall SARS-CoV-2 infection, COVID-19 hospitalizations, severe disease and related deaths during the Delta variant surge compared with those who received two doses five months or longer prior to the potential exposure.

Authors: Khitam Muhsen, Ph.D., of Tel Aviv University, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link 


Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.